Connect with us

Emerging Markets

Rushnet Inc (OTCMKTS: RSHN) Heating Up as Co Prepares for HeliosDX Spinoff, Dividend & New RushNet

Published

9 months ago

on

Rushnet Inc (OTCMKTS: RSHN) is on the move as the Company makes big strides forward as shareholders prepare for the heliosDX spinoff, dividend, and a new RushNet. Management has been working hard behind the scenes recently announcing on twitter CEO Ashley Sweat is working to return nearly 400M of his shares to $RSHN. The Company plans to lower the Authorized Shares by approximately 1B to further demonstrate no dilution more dilution. RSHN has a history of big moves skyrocketing to over $0.027 in summer 2021. 

RSHN is planning to spinoff heliosDX and Grandeza Healthcare with new shares in the Company distributed to current shareholders.. heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The Company is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. In the last few months, heliosDX has processed over 1,000 medically necessary physician ordered tests, and billed nearly one million dollars without reimbursement or substantiated justification. heliosDX expanded its Infectious Disease PCR panel to include the Human Monkeypox Virus; launched earlier this year through its partner laboratory, the Human Monkeypox Virus testing is in line with the ambitious vision management has for the Company working on a number of major acquisitions to help grow the business exponentially. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Rushnet Inc (OTCMKTS: RSHN) operating out of Orange Park, Florida has transformed over the past year into a revenue powerhouse with the acquisition of heliosDX; a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. heliosDX is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. Always staying ahead of the curve, by continually investing in its infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. The Company excels in patient and client care through physician designed panels that aid in testing compliance and reporting education. heliosDX as the first step to bring value to shareholders. The has company progressed in the last few months and plans future acquisitions to bolster company and shareholder value.  Rushnet currently operates as heliosDX and Grandeza Healthcare; a healthcare billing and consulting company. Providing expert billing and coding services to laboratories, medical practices, dental offices, and other medical verticals.  In addition to billing, Grandeza Healthcare provides Revenue Cycle Management (RCM) for all clients, as well as customized consulting services. Grandeza is a rapidly growing company adding new services and value to further demonstrate our competitive advantage.  

heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, and Infectious Disease (PCR). We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. heliosDX intends to always stay ahead of the curve by continually investing in our infrastructure with the most efficient scientific proven instruments and latest cutting-edge software for patient and physician satisfaction. In the last few months, heliosDX has processed over 1,000 medically necessary physician ordered tests, and billed nearly one million dollars without reimbursement or substantiated justification. heliosDX revenues are growing fast. During 2021 heliosDX did $5,893,984 in total revenues from Billing services and Laboratory testing fees. During Q2, 2022 heliosDX reported $1,977,761 in revenues putting the Company on track to generate over $7.5 million in annual revenues for 2022. Last year heliosdDX acquired a privately held laboratory with $10,000,000 annual revenues processing more than 5,000 tests monthly with a capacity of 12,000 monthly UDS tests. heliosDX and RushNet Inc. sign to acquire this laboratory gaining strategic benefits regarding location and contracting potential. heliosDX continues to search the market for additional laboratories for acquisition. A third laboratory has been identified and preliminary numbers shared, but negotiations have yet to begin.

According to a recent update from the Company, the Rushnet, Inc. of the past is long gone. However, remnants of its historical dealings still cling to the business that have posed challenges to current management as it navigates the public sector in pursuit of the long-term goals that we’ve set for the current Rushnet. Today, we have a completely new face, new management and new goals within the National Diagnostics Laboratory and the Healthcare Billing and Coding space which is operating today as heliosDX and Grandeza Healthcare. The services and objectives of today are completely different and have an ultimate goal of continuing the enhancement of shareholder value. As in life, a business can be presented with various paths to choose in order to stay the course and achieve its ultimate long-term vision. The company’s (heliosDX and Grandeza Healthcare) goals have not changed: grow the business to $50 million in revenue in three years and thereby increase shareholder value. The company has not wavered from this target and aims to accomplish this vision. The main primary target on this long-term path has been to acquire another toxicology laboratory that we know will greatly benefit the business and its shareholders.  

ImageheliosDX Spinoff: Earlier this year RSHN announced the proposed Rushnet dividend of heliosDX shares planned to be issued upon the spinoff of heliosDX. This proposed structure is free of any dilution to Rushnet – no additional shares of RushNet will be consumed in the process – it will have the same number of shares outstanding as it does now. As part of the 15-month plan, Rushnet and its subsidiaries, heliosDX and Grandeza Healthcare, recently announced the completion of the PCAOB audit. This necessary and crucial step was needed in order to proceed with: (1) the issuance of dividend shares of the future heliosDX, Inc. to current RSHN shareholders and (2) the raising of $20,000,000 through the filing of a Tier 2, Regulation A with the SEC. Shares of heliosDX, not shares of RushNet, will be offered as part of the public offering. Through the public offering of heliosDX shares from the Regulation A, heliosDX plans to raise $20,000,000 for future business endeavors. These heliosDX shares to be distributed to RushNet shareholders as well as the fundraising element, are to be qualified by the Regulation A Offering to be free trading shares. For every six hundred and fifty (650) shares of RSHN owned, shareholders will receive one (1) share of heliosDX, Inc. 

For the Inside Scoop on Rushnet Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RSHN

Earlier this year heliosDX expanded its Infectious Disease PCR panel to include the Human Monkeypox Virus. Due to the rising concern and surge of reported cases of the Monkeypox Virus in the United States, heliosDX is adding testing to its infectious disease panel immediately. Together with its lab partners the Company is responding to the growing need of testing to identify the virus accurately and in turn to allow physicians and clinics nationwide to effectively treat patients that are suffering. heliosDX also aunched its testing for the Human Monkeypox Virus through its partner laboratory.

More recently the Company announced heliosDX is reaching out across the U.S. to promote its services in collaboration with its lab partner for the Human Monkeypox Virus. heliosDX utilizes its CRM powered by SharpSpring to market the company and promote its services nationwide. The company is sending out a marketing campaign nationwide to promote its testing services for Human Monkeypox virus. This rising concern and increase in outbreaks has led heliosDX and its partner to act fast and to add PCR testing for the virus. The laboratory conducted test is available and the kits are ready for shipment. As reported by the CDC, the virus has reached 9,492 cases in the US as of August 9th, 2022 with the hardest hit states being NY, CA, and then FL.  

On September 2 RSHN announced heliosDX will absorb Grandeza Healthcare in preparation for the spinout from Rushnet. As of October 1st, 2022, Grandeza Healthcare will be completely rolled into heliosDX to include all income, assets, liabilities, personnel, and services. It is evident that this will benefit both Rushnet and heliosDX by streamlining operations and reducing costs. Danielle Bauer, CEO of Grandeza Healthcare, has been offered a role within heliosDX as Director of Compliance and Operations. Upon completion of the heliosDX spinout, Rushnet will remain a publicly traded company, which is pink current, clean, PCAOB audited, and ready for its next venture which will be publicly announced in the coming months. heliosDX upon spinoff will have a foundation of approximately 13,000,000 shares, which will be freely tradeable and consider the float. 

Final note, as of September 2, 2022, BMD, which is the counsel for Rushnet and heliosDX, has submitted the Company’s Finra response to include many corporate actions at the state (NV and CO) level spanning the last 20 years. Rushnet has also submitted payment to Nevada to clear up back taxes of approximately $43,000. This clears the path along with multiple corporate actions for a swift and expeditious approval of the spinoff and dividend. 

Fore more on RSHN Subscribe Right Now!

Currently trading at a $17 million market valuation Rushnet is an exciting story developing in small caps; currently shareholders are preparing for the heliosDX spinoff, dividend, and a new RushNet. Management has been working hard behind the scenes recently announcing on twitter CEO Ashley Sweat is working to return nearly 400M of his shares to $RSHN. The Company plans to lower the Authorized Shares by approximately 1B to further demonstrate no dilution more dilution. RSHN has a history of big moves skyrocketing to over $0.027 in summer 2021. RSHN is planning to spinoff heliosDX and Grandeza Healthcare with new shares in the Company distributed to current shareholders.. heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The Company is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. In the last few months, heliosDX has processed over 1,000 medically necessary physician ordered tests, and billed nearly one million dollars without reimbursement or substantiated justification. heliosDX expanded its Infectious Disease PCR panel to include the Human Monkeypox Virus; launched earlier this year through its partner laboratory, the Human Monkeypox Virus testing is in line with the ambitious vision management has for the Company working on a number of major acquisitions to help grow the business exponentially. We will be updating on RSHN when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in RSHN either long or short and we have not been compensated for this article.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

5 days ago

on

May 31, 2023

By

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

2 weeks ago

on

May 21, 2023

By

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Emerging Markets

GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing

Published

3 weeks ago

on

May 14, 2023

By

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12.

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12. This represents an impressive 137% increase; the volume has been off the hook. If you look at their historical chart, $GSIT had meager volume, sometimes as low as 300 shares traded in a day. If you do the math, that’s less than $500 worth of shares traded in a day – safe to say it was virtually illiquid.

So what happened, and what drove the stock to trade 50M shares with filings or news releases?

After an in-depth examination, GSI Technology, Inc. appears to have experienced a notable turning point in its market trajectory. The catalyst for this transformation was the company’s prominent feature on Fox News, triggering an exponential dissemination of information across various platforms. It is worth highlighting an intriguing phenomenon that tends to transpire in such circumstances: purchasing shares often induces a ripple effect, encouraging further buying activity.

With Fox News bringing the company into the spotlight and stimulating investor interest, a domino effect occurred among astute day traders who eagerly seized the opportunity to partake in this promising venture. Consequently, the trading volume for GSI Technology, Inc. skyrocketed to unprecedented levels, surpassing all previously recorded thresholds.

This surge in volume stands as a testament to the immense enthusiasm that enveloped the market as traders recognized the tremendous potential inherent in $GSIT. This collective enthusiasm resulted in an extraordinary demonstration of market engagement, reflecting a widespread acknowledgment of the company’s significance and the opportunities it presents.

https://twitter.com/SamanthaLaDuc/status/1657033207412293634?s=20

This development showcases the power of influential media coverage and underscores the intriguing dynamics that can arise when investor sentiment aligns with a compelling market narrative.

To Discover the Inside Scoop on GSIT, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Founded in 1995, GSI Technology Inc. has established itself as a prominent provider of semiconductor memory solutions. The company is focused on introducing new products that capitalize on its core strengths, which include radiation-hardened memory products for extreme environments and Gemini, an advanced processing unit (APU) designed to enhance performance in various artificial intelligence (AI) applications. Headquartered in Sunnyvale, California, GSI Technology operates sales offices in the Americas, Europe, and Asia.

GSI Technology is on the verge of reporting its earnings next week, and the company operates in the storage business, which supports the development of highly efficient AI chips. Traditionally, computing involves separate chips for storage and computation, necessitating frequent data exchange. This process incurs significant power consumption and presents scalability challenges.

To address these limitations, GSI Technology has developed a groundbreaking solution called In-memory processing. This innovation substantially reduces computation time from minutes to seconds, milliseconds, or even microseconds. Notably, it also significantly diminishes power consumption and overall cost of ownership. The key to this improvement lies in the massive parallel data processing offered by GSI’s technology, featuring two million-bit processors per chip compared to thousands found in standard graphic processing units (GPUs). Consequently, the system becomes more scalable, enabling efficient and accelerated AI processing.

By streamlining the computing process and integrating storage and computation on a single chip, GSI Technology aims to revolutionize AI processing. This approach offers notable benefits regarding power efficiency, computational speed, and scalability, making it an attractive solution for a wide range of AI applications.

In conclusion, GSI Technology, Inc. is poised to deliver innovative semiconductor memory solutions emphasizing AI chip development. The company aims to reduce computation time, power consumption, and total ownership cost through its In-memory processing technology while significantly improving scalability. With its upcoming earnings report, investors and industry observers will closely watch the company’s progress in the storage business and AI chip development.

We will update you on GSIT when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with GSIT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.